Unlabelled: Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, fibroinflammatory cholangiopathy. The role of the microbiota in PSC etiopathogenesis may be fundamentally important, yet remains obscure. We tested the hypothesis that germ-free (GF) mutltidrug resistance 2 knockout (mdr2(-/-) ) mice develop a distinct PSC phenotype, compared to conventionally housed (CV) mdr2(-/-) mice. Mdr2(-/-) mice (n = 12) were rederived as GF by embryo transfer, maintained in isolators, and sacrificed at 60 days in parallel with age-matched CV mdr2(-/-) mice. Serum biochemistries, gallbladder bile acids, and liver sections were examined. Histological findings were validated morphometrically, biochemically, and by immunofluorescence microscopy (IFM). Cholangiocyte senescence was assessed by p16(INK4a) in situ hybridization in liver tissue and by senescence-associated β-galactosidase staining in a culture-based model of insult-induced senescence. Serum biochemistries, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were significantly higher in GF mdr2(-/-) (P < 0.01). Primary bile acids were similar, whereas secondary bile acids were absent, in GF mdr2(-/-) mice. Fibrosis, ductular reaction, and ductopenia were significantly more severe histopathologically in GF mdr2(-/-) mice (P < 0.01) and were confirmed by hepatic morphometry, hydroxyproline assay, and IFM. Cholangiocyte senescence was significantly increased in GF mdr2(-/-) mice and abrogated in vitro by ursodeoxycholic acid (UDCA) treatment.
Conclusions: GF mdr2(-/-) mice exhibit exacerbated biochemical and histological features of PSC and increased cholangiocyte senescence, a characteristic and potential mediator of progressive biliary disease. UDCA, a commensal microbial metabolite, abrogates senescence in vitro. These findings demonstrate the importance of the commensal microbiota and its metabolites in protecting against biliary injury and suggest avenues for future studies of biomarkers and therapeutic interventions in PSC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670294 | PMC |
| http://dx.doi.org/10.1002/hep.27927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Study on the mechanism of Fuzheng Huayu formula against biliary fibrosis in mice].
Zhonghua Gan Zang Bing Za Zhi
November 2024
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai201203, China Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Medicine, Shanghai201203, China.
Article Synopsis
- The study aimed to explore how the Fuzheng huayu formula (FZHY) affects biliary fibrosis in mice by comparing its effects with obeticholic acid (OCA) and a control group.
- Mice were treated with specific drugs over a 12-week period, and various liver health indicators, including serum enzyme levels and tissue markers, were analyzed using multiple biochemical techniques.
- Results demonstrated that both FZHY and OCA effectively reduced the harmful effects of fibrosis in the gene knockout mice by reversing elevated liver indicators, improving markers of liver function, and influencing specific molecular pathways related to inflammation and cellular response.
Background: Fibroinflammatory cholangiopathies, such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), are characterized by inflammation and biliary fibrosis, driving disease-related complications. In biliary fibrosis, cholangiocytes activated by transforming growth factor-β (TGFβ) release signals that recruit immune cells to drive inflammation and activate hepatic myofibroblasts to deposit the extracellular matrix (ECM). TGFβ regulates stearoyl-CoA desaturase (SCD), an enzyme that catalyzes the synthesis of monounsaturated fatty acids, in stimulating fibroinflammatory lipid signaling.
View Article and Find Full Text PDFOral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice.
Sci Rep
November 2024
Institute of Gastroenterology, Hepatology and Nutrition, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Article Synopsis
- - Cholangiopathies are complex disorders with limited understanding and no effective treatments, prompting a study on the extrahepatic biliary tree (EHBD) in Mdr2 mice, a cholestatic mouse model, across different ages (2 to 40 weeks).
- - The study assessed the effects of N-acetyl-L-Cysteine (NAC), an antioxidant and glutathione precursor, on EHBD injury both ex vivo (using bile duct samples) and in vivo (through oral administration for three weeks).
- - Results showed that NAC treatment improved bile duct morphology and reduced liver fibrosis along with lower liver enzyme levels, suggesting a shift in cellular state from apoptosis to proliferation, indicating NAC's potential as a therapeutic
Serum metabonomics reveal the effectiveness of human placental mesenchymal stem cell therapy for primary sclerosing cholangitis.
Stem Cell Res Ther
October 2024
State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City, 310003, China.
Article Synopsis
- The study looks at how a type of stem cell treatment from the placenta can help patients with a liver disease called primary sclerosing cholangitis (PSC).
- Researchers used special mice to see how the stem cell treatment affected their liver health and identified important substances in their blood to check its effectiveness.
- They found that after the treatment, certain harmful substances in the liver decreased while beneficial ones increased, suggesting the stem cell treatment was successful in improving liver function.
Extracellular Vesicle-Associated Neutrophil Elastase Activates Hepatic Stellate Cells and Promotes Liver Fibrogenesis via ERK1/2 Pathway.
bioRxiv
August 2024
Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine; University of Florida, Gainesville, Florida, USA.
Liver fibrosis associated with increased mortality is caused by activation of hepatic stellate cells and excessive production and accumulation of extracellular matrix in response to fibrotic insults. It has been shown that in addition to liver inflammation, systemic inflammation also contributes to liver fibrogenesis. A deeper understanding of mechanisms that control liver fibrotic response to intra- and extra-hepatic inflammation is essential to develop novel clinical strategies against this disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!